V. Talbot

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.

Paul D. Smith, Michal Bista, D. Hargreaves, 2021, Journal of medicinal chemistry.

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.

Fiona Pachl, A. Pike, M. O’Connor, 2021, Journal of medicinal chemistry.

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

Paul Hemsley, Joseph Shaw, Ian Dale, 2018, SLAS discovery : advancing life sciences R & D.

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Fiona Pachl, M. O’Connor, Glen Hawthorne, 2018, Experimental and Molecular Therapeutics.